BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

JPT Peptide Technologies GmbH Announces Cooperation On Systematic Identification Of Tuberculosis T-Cell Epitopes With Oregon Health & Science University (OHSU)


10/19/2005 5:09:25 PM

BERLIN--(BUSINESS WIRE)--July 6, 2005--JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of Jerini AG, today announced a collaboration with Oregon Health & Science University (OHSU) for the systematic and rapid discovery of T-cell epitopes to accelerate the development of vaccines against tuberculosis (TB). The collaboration combines OHSU's outstanding research and expertise to isolate and clone CD8+ cells from latent TB patients with JPT's proprietary SPOT(TM) technology to produce very large numbers of peptides. David and Deborah Lewinsohn at OHSU are principal investigators of an NIH/ NIAID biodefense contract to study tuberculosis. Their teams determine relevant antigens within infected cells, which subsequently will be used to identify characteristic parts of these proteins (epitopes) that are required by the CD8+ cells to activate the immune response against these bacteria.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES